Cohort study to evaluate the effect of vitamin D, magnesium, and vitamin B12 in combination on progression to severe outcomes in older patients with coronavirus (COVID-19)
Chuen Wen Tan, Liam Pock Ho, Shirin Kalimuddin, Benjamin Pei Zhi Cherng, Yii Ean Teh, Siew Yee Thien, Hei Man Wong, Paul Jie Wen Tern, Manju Chandran, Jason Wai Mun Chay, Chandramouli Nagarajan, Rehena Sultana, Jenny Guek Hong Low, Heng Joo Ng
Nutrition, doi:10.1016/j.nut.2020.111017
The aim of this study was to determine clinical outcomes of older patients with coronavirus (COVID-19) who received a combination of vitamin D, magnesium, and vitamin B 12 (DMB) compared with those who did not. We hypothesized that fewer patients administered this combination would require oxygen therapy, intensive care support, or a combination of both than those who did not. Methods: This was a cohort observational study of all consecutive hospitalized patients 50 y of age with COVID-19 in a tertiary academic hospital. Before April 6, 2020, no patients received the (DMB) combination. After this date, patients were administered 1000 IU/d oral vitamin D 3 , 150 mg/d oral magnesium, and 500 mcg/d oral vitamin B 12 upon admission if they did not require oxygen therapy. Primary outcome was deterioration leading to any form of oxygen therapy, intensive care support, or both. Results: Between January 15 and April 15, 2020, we identified 43 consecutive patients 50 y of age with COVID-19. Seventeen patients received DMB before onset of primary outcome and 26 patients did not. Baseline demographic characteristics between the two groups were significantly different by age. In univariate analysis, age and hypertension had a significant influence on outcome. After adjusting for age or hypertension separately in a multivariate analysis, the intervention group retained protective significance. Fewer treated patients than controls required initiation of oxygen therapy during hospitalization (17.6 vs 61.5%, P = 0.006). DMB exposure was associated with odds ratios of 0.13 (95% confidence interval [CI], 0.03À0.59) and 0.20 (95% CI, 0.04À0.93) for oxygen therapy, intensive care support, or both on univariate and multivariate analyses, respectively. Conclusions: A vitamin D / magnesium / vitamin B 12 combination in older COVID-19 patients was associated with a significant reduction in the proportion of patients with clinical deterioration requiring oxygen
References
Dai, Zhu, Manson, Song, Li et al., Magnesium status and supplementation influence vitamin D status and metabolism: results from a randomized trial, Am J Clin Nutr
Degnan, Taga, Goodman, Vitamin B12 as a modulator of gut microbial ecology, Cell Metab
Dhar, Mohanty, Gut microbiota and Covid-19-possible link and implications, Virus Res
Martineau, Jolliffe, Hooper, Greenberg, Aloia et al., Vitamin D supplementation to prevent acute respiratory tract infections: systemic review and meta-analysis of individual participant data, BMJ
Negi, Das, Pahari, Nadeem, Agrewala, Potential role of gut microbiota in induction and regulation of innate immune memory, Front Immunol
Pan, Mu, Yang, Sun, Wang et al., Clinical characteristics of COVID-19 patients with digestive symptoms in Hubei, China: a descriptive, cross-sectional, multicenter study, Am J Gastroenterology
Shechter, Merz, Paul-Labrador, Meisel, Rude et al., Oral magnesium supplementation inhibits platelet-dependent thrombosis in patients with coronary artery disease, Am J Cardiol
Verity, Okell, Dorigatti, Wiskill, Whittaker et al., Estimates of the severity of coronavirus disease 2019: a model-based analysis, Lancet Infect Dis
Zuo, Zhang, Lui, Yeoh, Li et al., Alterations in gut microbiota of patients with COVID-19 during time of hospitalization, Gastroenterology
